Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: mike head who wrote (213)	3/16/1998 9:06:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 656

Here's what thestreet.com had to say about IL-4 a month or two ago: A new class, and one that is likely to perform the best, attacks the most fundamental of the mediators, IL-4. IL-4 is the first mediator to be released, and it starts the chain of events that ultimately results in the symptoms of asthma. Inhibiting or circumventing IL-4 will be critical. From this perspective, I give a thumbs up to Glaxo Wellcome, Ligand (LGND:Nasdaq) and Immunex (IMNX:Nasdaq). Of these three, Immunex is the furthest along in the development process, and its data, to be presented at the American Association of Allergy, Asthma and Immunology conference this March, will be most interesting.